
Ashley Gold reports 3.333 g/t over 60 metres at Tak
Hole TAK-26-16 includes 229 grams per tonne gold over 0.65 metre, with results from four Phase III holes pending.

An unnamed AI lab committed to enter a separate ten-year Barber Lake lease after Fluidstack's term; first rent commencement is expected in the fourth quarter of 2026.

Hole TAK-26-16 includes 229 grams per tonne gold over 0.65 metre, with results from four Phase III holes pending.

The term starts when Building One is ready for service; Fermi gave no date or contract value in its Sept. 24 announcement.
The first 556,500-ounce reserve backs an 8.5-year Granite Creek plan, with Lone Tree processing scheduled for late 2027.
The Sept. 25 meeting lacked quorum, leaving shareholders until 9 a.m. EDT on Oct. 23 to submit proxies before the reconvened vote.

OPG's Sept. 25 supplier post names ATS's tooling and a 125,000-square-foot facility addition without stating a contract value or delivery date.

SIDEX and NQ Mining Investment lead the flow-through sale, priced at C$0.145 a share and expected to close about Sept. 29.

COL forecasts €250 million in 2027 sales; Eaton expects the acquisition to close in the first quarter, subject to approvals.

The application seeks dosing for smaller children with APDS, and the FDA set Jan. 30, 2027 as its target action date.
The Sept. 25 weekly update lists 288.1 BTC mined and zero net coins added; Friday's Nasdaq close predates the post.
The seven-year CPU services agreement carries delivery conditions, a preferred-share warrant and a projected late 2027 service start.
Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.
The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.
A Sept. 24 federal notice opens intervention in Transco's Pennsylvania pipeline application, while Williams targets late 2027 service.
Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.
A CAD administration role accounts for US$57,127 of the forecast; a US$3.43M ten-year value depends on continued authorization.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Its July placement issued 35.98 million shares and matching warrants, while the latest notice disclosed $334,577 in finder fees.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Mirum expects U.S. availability in October after a 63-patient study; its prespecified new-lesion incidence endpoint missed the conventional threshold.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The Swiss cybersecurity group expects Oct. 2 to be the last session for its existing ADSs and Class B shares before a planned WISeQey listing.
Rexel plans about €800M in cash and debt and may raise up to €500M in equity before a targeted 2026 year-end close.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Selected historic core from Colombia also held magnet rare earth oxides, but continuity and recovery remain untested.

The 1-for-10 plan has shareholder approval but still needs TSX Venture Exchange acceptance; Dev Randhawa becomes executive chair.

June-quarter sales fell to about US$13,500, while a post-year-end secured loan added US$20 million in initial funding.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Aurora cites missing pro forma financials, a French-language notice and the mandatory 105-day deposit period in its ASC application.

Advisers voted 10 to 0 on safety and 6 to 4 on effectiveness; the FDA has not set a date for its final decision.

A 51 per cent stake in a Polish drone company remains a non-binding proposal, while the registered share sale is expected to close Sept. 24.

The Health Canada-authorized depression study plans to enroll up to 200 people, while the batch also serves Australian clinics.